Autologous T cells are genetically engineered to express a chimeric antigen receptor (often targeting CD19) that recognizes tumor antigens independent of MHC, activating the T cells to proliferate and kill antigen-positive malignant B cells via cytotoxic mechanisms (perforin/granzyme) and cytokine release.